News | April 12, 2012

Maryland Law Requires Peer Review of Coronary Stents Implants

Cardiologists praise assembly because of help adhering to evidence-based medicine

April 12, 2012 — The Maryland General Assembly set a high bar for the nation and showed its commitment to patients by passing legislation establishing an independent review of the placement of stents in heart patients to ensure consistency with guidelines developed by the American College of Cardiology and other organizations, the Maryland Chapter of the American College of Cardiology said.

“An independent peer review process is critical to continuously assess patient safety and to ensure quality care for this essential, life-saving service,” said chapter President Marc Mugmon, M.D., FACC.

The Maryland Chapter of the American College of Cardiology proactively sought legislation last year to deal with the inconsistent utilization of peer review and its proposals were adopted as an amendment to HB 1141. The chapter was the catalyst in seeking enhanced independent, external peer review.

The Maryland chapter, at the invitation of the Maryland Health Care Commission, will be an integral part of the regulatory process to implement regulations and ongoing performance measures as a member of the newly established Clinical Advisory Group.

"The cardiovascular community, especially members of the American College of Cardiology, look forward to working with the Maryland Health Care Commission to develop regulations for peer review,” Mugmon said.

“The peer review component of the bill, which requires the development of minimum standards in the next year, will set a national precedent in cardiac care,” Mugmon said. “Peer review is a fundamental component of any comprehensive continuous quality improvement effort and will enhance patient safety by providing constructive, objective feedback to cardiologists in a collaborative environment.”

“Independent, external review will be free of bias and politics, and by identifying individual operator strengths and weaknesses, it will help achieve the highest standard of performance,” Mugmon said. “This process will complement robust internal programs and will rapidly identify and address potential deviations from accepted evidence-based guidelines for the use of stents.”

The Maryland Chapter, led by past-President Samuel Goldberg, M.D., FACC, and assisted by a team of clinical, interventional and academic cardiologists throughout the state, advocated for this legislation for the past two years.

“We are grateful that the Maryland Health Care Commission and the general assembly listened and finally understand the importance of this legislation to heart patients in Maryland,” Goldberg said. “We hope this will serve as a model for other states.”

The bill now goes to Governor Martin O’Malley for signature.

For more information:

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init